Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Cancer. 2010 Oct 19;117(6):1113–1122. doi: 10.1002/cncr.25527

Figure 5.

Figure 5

Progression- and event-free survival rates at 5 years by molecular response at 6 months.30

This research was originally published in Blood. Muller MC, Hanfstein B, Erben P, et al. Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia - An Interim Analysis of the Randomized German CML Study IV. Blood. 2008;112(11):129. © the American Society of Hematology.